Advances in the treatment of polycystic ovary syndrome

Bibliography

• FRANKS S: Polycystic ovary syndrome. N Engl. J. Med. (1995) 333:853–861.
   PubMed Web of Science ®Google Scholar
• DAHLGREN E, JANSON PO, JOHANSSON S, LAPIDUS L, ODEN A: Polycystic ovary syndrome and risk for myocardial infarction. Acta Obstet. Cyriecol Scam/ (1992) 71:599–603.
   PubMed Web of Science ®Google Scholar
• DUNAIF A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Eridocr. Rev (1997) 18:774–800.
   PubMed Web of Science ®Google Scholar
• LOBO RA, CARMINA E: The importance of diagnosing the polycystic ovary syndrome. Ann. Intern. Med. (2000) 132:989–993.
   PubMed Web of Science ®Google Scholar
• GUZICK DS, TALBOTT EO, SUTTON-TYRRELL K, HERZOG HC, KULLER LH, WOLFSON SK: Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am. I Obstet. Cyriecol (1996) 174:1224–1232.
   PubMed Web of Science ®Google Scholar
• BIRDSALL MA, FARQUHAR CM, WHITE HD: Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann. Intern. Med. (1997) 126:32–35.
   PubMed Web of Science ®Google Scholar
• CIBULA D, CIFKOVA R, FANTA M, POLEDNE R, ZIVNY J, SKIBOVA J: Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum. Reprod. (2000) 15:785–789.
   PubMed Web of Science ®Google Scholar
• WILD S, PIERPOINT T, MCKEIGUE E JACOBS H: Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. OM. Endocrine]. (2000) 52:595–600.
   Google Scholar
• EHRMANN DA, BARNES RB, ROSENFIELD RL, CAVAGHAN MK, IMPERIAL J: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care (1999) 22:141–146.
   PubMed Web of Science ®Google Scholar
• LEGRO RS, KUNSELMAN AR, DODSON WC, DUNAIF A: Prevalence and predictors of risk for Type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. OM. Endocrine]. Metab. (1999) 84:165–169.
   PubMed Web of Science ®Google Scholar
• WILD RA: Obesity, lipids, cardiovascular risk, and androgen excess. Am. I Med. (1995) 98(Suppl. 1A):275–325.
   Google Scholar
• MATHER KJ, KWAN E CORENBLUM B: Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Feral. Steril. (2000) 73:150–156.
   PubMed Web of Science ®Google Scholar
• TALBOTT E, GUZICK D, CLERICI A et al.: Coronary heart disease risk factors in women with polycystic ovary syndrome. Arteriascier. Diramb. Vase. Bid. (1995) 15:821–826.
   PubMed Web of Science ®Google Scholar
• DAHLGREN E, JOHANSSON S, LINDSTEDT G et al.:Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Feral. Steril. (1992) 57:505–513.
   PubMed Web of Science ®Google Scholar
• HOLTE J, GENNARELLI G, BERNE C,BERGH T, LITHELL H: Elevated ambulatory day-time pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum. Reprod. (1996) 11:23–28.
   Web of Science ®Google Scholar
• TOSCANO V, ADAMO MV, CAIOLA S et al.: Is hirsutism an evolving syndrome?I Endocrine]. (1983) 97:379–387.
   Google Scholar
• PORETSKY L: On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Eridocr. Rev (1991) 12:3–13.
   PubMed Web of Science ®Google Scholar
• RITTMASTER RS: Medical treatment of androgen-dependent hirsutism. I OM. Endocrine]. Metab. (1995) 80:2559–2563.
   PubMed Web of Science ®Google Scholar
• ABBOTT DH, DUMESIC DA, EISNER JR, KENMITZ JW, GOY RW: The prenatally androgenized female rhesus monkey as a model for PCOS. In: Azziz R. Nestler J.E. Dewailly D, eds. Androgen excess disorders in women. Lippincott-Raven, Philadelphia (1997):369–382.
   Google Scholar
• GIVENS JR, ANDERSEN RN, WISER WL, DONELSON AJ, COLEMAN SA: A testosterone-secreting, gonadotropin-responsive pure thecoma and polycystic ovarian disease. j OM. Endocrine]. Metab. (1975) 41:845–853.
   PubMed Web of Science ®Google Scholar
• DEWAILLY D, VANTYGHEM-HAUDIQUET MC, SAINSARD C et al.: Clinical and biological phenotypes in late-onset 21-hydroxylase deficiency. Endocrine]. Metab. (1986) 63:418–423.
   PubMed Web of Science ®Google Scholar
• HOMBURG R, AMSTERDAM A: Polycystic ovary syndrome - loss of the apoptotic mechanism in the ovarian follicles? J. Endocrine]. Invest. (1998) 21:552–557.
   PubMed Web of Science ®Google Scholar
• WEIL SJ, VENDOLA K, ZHOU J et al.: Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. OM. Endocrine]. Metab. (1998) 83:2479–2485.
   PubMed Web of Science ®Google Scholar
• DUNAIF A: Do androgens directly regulategonadotropin secretion in the polycystic ovary syndrome? I OM. Endocrine]. Metab. (1986) 63:215–221.
   PubMed Web of Science ®Google Scholar
• EAGLESON CA, GINGRICH MB, PASTOR CL et al.: Polycystic ovary syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. Endocrine]. Metab. (2000) 85:4047–4052.
   PubMed Web of Science ®Google Scholar
• MOGHETTI, F. TOSI, R. CASTELLO et al.: The insulin resistance in women with hyperandrogenism is partially reversed by anti-androgen treatment: evidence that androgens impair insulin action in women. OM. Endocrine]. Metab. (1996) 81:952–960.
   Google Scholar
• BJORNTORP P: Abdominal obesity and the development of non insulin-dependent diabetes mellitus. Diabetes Metab. Rev (1988) 4:615–622.
   PubMed Web of Science ®Google Scholar
• FERRANNINI E, BARRETT EJ, BEVILACQUA S, DEFRONZO RA: Effect of fatty acids on glucose production and utilization in man. j OM. Invest. (1983) 72:1737–1747.
   PubMed Web of Science ®Google Scholar
• HOLTE J, BERGH T, BERNE C, BERGLUND L, LITHELL H: Enhanced insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. ..J. OM. Endocrine]. Metab. (1994) 78:1052–1058.
   PubMed Web of Science ®Google Scholar
• HOLTE J, BERGH T, BERNE C, WIDE L, LITHELL H: Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. Endocrine]. Metab. (1995) 80:2586–2593.
   PubMed Web of Science ®Google Scholar
• RODIN A,THAKKAR H, YAYLOR N, CLAYTON R: Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 1 lb-hydroxysteroid dehydrogenase. N Engl. j Med. (1994) 330:460–465.
   Google Scholar
• LANZONE A, PETRAGLIA F, FULGHESU AM, CIAMPELLI M, CARUSO A, MANCUSO S: Corticotropin-releasing hormone induces an exaggerated response of adrenocorticotropic hormone and cortisol in polycystic ovary syndrome. Ferell. Steril. (1995) 63:1195–1199.
   PubMed Web of Science ®Google Scholar
• DE LEO V, LANZETTA D, D'ANTONA D, LA MARCA A, MORGANTE G: Hormonal effects of flutamide in young women with polycystic ovary syndrome. Chic Eridocnnol. Metab. (1998) 83:99–102.
   PubMed Web of Science ®Google Scholar
• FALASCA P, POGGI M, STIGLIANO A, MONTI S, SCIARRA F, TOSCANO V: Flutamide effects on hirsutism, acne, menstrual cyclicity and ovulation restoration. Proc. 83rd Annual Meeting of the Endocrine Society Denver, CO, USA (2001) (Abst.) P2–462.
   Google Scholar
• DIAMANTI-KANDARAKIS E, MITRAKOU A, RAPTIS S, TOLIS G, DULEBA AJ: The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. j Chic Eridoctiriol. Metab. (1998) 83:2699–2705.
   PubMed Web of Science ®Google Scholar
• IBANEZ L, POTAU N, MARCOS MV, DE ZEGHER F: Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. j Gun. Eridocnnol. Metab. (2000) 85:3251–3255.
   PubMed Web of Science ®Google Scholar
• TAYLOR AE, MCCOURT B, ANDERSON EJ etal.: Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovarian syndrome. j Gum. Eridocnnol. Metab. (1997) 82:2248–2256.
   Google Scholar
• REBAR R, JUDD HL, YEN SSC, RAKOFF J, VANDENBERG G, NAFTOLIN F: Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. j Clin. Invest. (1976) 57:1320–1329.
   PubMed Web of Science ®Google Scholar
• PASTOR CL, GRIFFIN-KORF ML, ALOI JA, EVANS WS, MARSHALL JC: Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. Eridoctiriol. Metab .(1998) 83:582–590.
   Web of Science ®Google Scholar
• DUMESIC DA, ABBOTT DH, EISNER JR, GOY RW: Prenatal exposure of female rhesus monkeys to testosterone propionate increases serum luteinizing hormone levels in adulthhod. Fertil. Steril. (1997) 67:155–163.
   PubMed Web of Science ®Google Scholar
• ROBINSON JE, FORSDIKE RA, TAYLOR JA: In utero exposure of female lambs to testosterone reduces the sensitivity of the gonadotropin-releasing hormone neuronal network to inhibition by progesterone. Endocrinology (1999) 140:5797–5805.
   PubMed Web of Science ®Google Scholar
• EAGLESON CA, GINGRICH MB, HU Y, MARSHALL JC: Metformin does not enhance sensitivity of the hypothalamic GnRH pulse generator to progesterone in women with PCOS. Proc. 83rd Annual Meeting of the Endocrine Socieni, Denver CO, USA (2001) (Abstract) P2–435.
   Google Scholar
• VELAZQUEZ EM, MEND OZA S, HAMER T, SOSA F, GLUECK CJ: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism (1994) 43:647–654.
   PubMed Web of Science ®Google Scholar
• NESTLER JE, JAKUBOWICZ DJ: Decreases in ovarian cytochrome P450c17a activity and serum free testosterone after reduction in insulin secretion in polycystic ovary syndrome. N Engl. I Med. (1996) 335:617–623.
   PubMed Web of Science ®Google Scholar
• JAKUBOVICZ DJ, NESTLER JE: Leanwomen with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a activity and serum androgens. I Clin. Eridocnnol. Metab. (1997) 82:4075–4079.
   PubMed Web of Science ®Google Scholar
• VELAZQUEZ E, ACOSTA A, MENDOZA SG: Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet. Cyriecol. (1997) 90:392–395.
   Web of Science ®Google Scholar
• DUNAIF A, SCOTT D, FINEGOOD D, QUINTANA B, WHITCOMB R: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. I Clin. Eridocnnol. Metab. (1996) 81:3299–3306.
   PubMed Web of Science ®Google Scholar
• MOGHETTI P, CASTELLO R, NEGRI C et al.: Metformin effects on clinical features, endocrine and metabolic profiles and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. Eridocrinol. Metab. (2000) 85:139–146.
   PubMed Web of Science ®Google Scholar
• EHRMANN DA, SCHNEIDER DJ, SOBEL BE et al.: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. Eridocrinol. Metab. (1997) 82:2108–2116.
   PubMed Web of Science ®Google Scholar
• AZZIZ R, EHRMANN D, LEGRO RS et al.: Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double-blind, placebo-controlled trial. I Clin. Eridocrinol. Metab. (2001) 86:1626–1632.
   PubMed Web of Science ®Google Scholar
• GODSLAND IF, CROOK D, SIMPSON R etal.: The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl. J. Med. (1990) 323:1375–1381.
   Google Scholar
• WINKLER UH. Blood coagulation and oral contraceptives. A critical review. Contraception (1998) 57:203–209.
   PubMed Web of Science ®Google Scholar
• THOROGOOD M. Stroke and steroid hormonal contraception. Contraception (1998) 57:157–67.
   PubMed Web of Science ®Google Scholar
• CHRISTMAN GM, RANDOLPH JF, KELCH RE MARSHALL JC: Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian syndrome. I Clin. Eridocnnol. Metab. (1991) 72:1278–1285.
   PubMed Web of Science ®Google Scholar
• CHANG RJ, LAUFER LR, MELDRUM DR et al.: Steroid secretion in polycystic ovary disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. I Clin. Eridocrinol. Metab. (1983) 56:897–903.
   PubMed Web of Science ®Google Scholar
• DE ZIEGLER D, STEINGOLD K, CEDARS M et al.:Recovery of hormone secretion after chronic GnRH-agonist administration in women with polycystic ovarian disease. I Clin. Eridocnnol. Metab. (1989) 68:1111–1117.
   PubMed Web of Science ®Google Scholar
• GENAZZANI AD, PETRAGLIA F, BATTAGLIA C et al.: A long-term treatment with gonadotropin-releasing hormone agonist plus a low-dose oral contraceptive improves the recovery of the ovulatory function in patients with polycystic ovary syndrome. Feral Sterll. (1997) 67:463–468.
   PubMed Web of Science ®Google Scholar
• GENAZZANI AD, BATTAGLIA C, GAMBA 0, PETRAGLIA F, MALAVASI B, GENAZZANI AR: The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycystic ovary disease after discontinuation of treatment. I Assist. Reprod. Genet. (2000) 17:269–275.
   PubMed Web of Science ®Google Scholar
• TOSI F, NEGRI C, BRUN E etal.: Menstrual pattern after transient gonadotropin and androgen suppression in women with polycystic ovary syndrome. Endocrine] Invest. (1997) 20 (Suppl.):Abst. 318.
   Google Scholar
• BARBIERI RL, MAKRIS A, RANDALL RW, DANIELS G, KRISTNERRW, RYAN KJ: Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. j Clirr. Endocrine] Metab. (1986) 62:904–910.
   PubMed Web of Science ®Google Scholar
• NESTLER JE, JAKUBOWICZ DJ, DE VARGAS AF, BRIK C, QUINTERO N, MEDINA F: Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. j CM]. Endocnnol Metab. (1998) 83:2001–2005.
   PubMed Web of Science ®Google Scholar
• NESTLER JE, POWERS LP, MATT DW: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. j OM. Endocrine] Metab. (1991) 72:83–89.
   PubMed Web of Science ®Google Scholar
• MOGHETTI E CASTELLO R, NEGRI C et al: Insulin infusion amplifies 17a-hydroxycorticosteroid intermediates response to ACTH in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. I OM. Endocrine] Metab. (1996) 81:881–886.
   PubMed Web of Science ®Google Scholar
• ADASHI EY, HSUEH AJW, YEN SCC: Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology(1981) 108:1441–1449.
   PubMed Web of Science ®Google Scholar
• NESTLER JE, BARLASCINI CO, MATT DW et al.: Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. I OM. Endocrine] Metab. (1989) 68:1027–1032.
   PubMed Web of Science ®Google Scholar
• PRELEVIC GM, WURZBURGER MI, BALINT-PERIC L, NESIC JS: Inhibitory effect of sandostatin on luteinizing hormone and ovarian steroids in polycystic ovary syndrome. Lancet (1990) 336:900–903.
   PubMed Web of Science ®Google Scholar
• PASQUALI R, ANTENUCCI D, CASIMIRRI F et al:Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. I OM. Endocrine] Metab. (1989) 68:173–179.
   PubMed Web of Science ®Google Scholar
• KIDDY DS, HAMILTON-FAIRLEY D, BUSH A, SHORT E ANYAOKU V, REED MJ: Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin. Endocrine] (1992) 36:105–111.
   PubMed Web of Science ®Google Scholar
• JAKUBOWICZ DJ, NESTLER JE: 17a-hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. I OM. Endocrine] Metab. (1997) 82:556–560.
   PubMed Web of Science ®Google Scholar
• BAILEY CJ, PATH MRC, TURNER RC: Metformin. N Engl. I Med. (1996) 334:574–579.
   PubMed Web of Science ®Google Scholar
• SALTIEL AR, OLEFSKY JM: Thiazolidinediones in the treatment of insulin resistance and Type II diabetes. Diabetes (1996) 45:1661–1669.
   PubMed Web of Science ®Google Scholar
• MURPHY E, NOLAN JJ: Insulin sensitizer drugs. Expert Opin Investig. Drugs (2000) 9:1347–1361.
   PubMed Web of Science ®Google Scholar
• NESTLER JE, JAKUBOWICZ DJ, EVANS WS, PASQUALI R: Effects of metformin on spontaneus and clomiphene-induced ovulation in the polycystic ovary syndrome. N Eng] I Med. (1998) 338:1876–1880.
   PubMed Web of Science ®Google Scholar
• DIAMANTI-KANDARAKIS E, KOULI C, TSIANATELI T, BERGIELE A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur. Endocrine] (1998) 138:269–274.
   PubMed Web of Science ®Google Scholar
• MORIN-PAPUNEN LC, KOIVUNEN RM, RUOKONEN A, MARTIKAINEN HK: Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Feral Sterif (1998) 69:691–696.
   PubMed Web of Science ®Google Scholar
• DE LEO V, LA MARCA A, DITTO A, MORGANTE G, CIANCI A: Effect of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Feral Stern. (1999) 72:282–285.
   PubMed Web of Science ®Google Scholar
• PIRWANY IR, YATES RW, CAMERON IT, FLEMING R: Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhea. Hum. Reprod. (1999) 14:2963–2968.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, WANG E FONTAINE R, TRACY T, SIEVE-SMITH L: Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism (1999) 48:511–519.
   PubMed Web of Science ®Google Scholar
• UNLUHIZARCI K, KELESTIMUR F, BAYRAM F, SAHIN Y, TUTUS A: The effect of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. OM. Endocnnol (1999) 51:231–236.
   Web of Science ®Google Scholar
• KOLODZIEJCZYK B, DULEBA AJ, SPACZYNSKI RZ, PAWELCZYK L: Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fern] Steril. (2000) 73:1149–1154.
   PubMed Web of Science ®Google Scholar
• PASQUALI R, GAMBINERI D, BISCOTTI D et al.: Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. OM. Endocrine] Metab. (2000) 85:2767–2774.
   PubMed Web of Science ®Google Scholar
• MORIN-PAPUNEN LC, VAUHKONEN I, KOIVUNEN RM, RUOKONEN A, MARTIKAINEN HK, TAPANAINEN JS: Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. I OM. Endocrine] Metab. (2000) 85:3161–3168.
   PubMed Web of Science ®Google Scholar
• IBANEZ L, VALLS C, POTAU N, MARC OS MV, DE ZEGHER F: Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. OM. Endocrine] Metab. (2000) 85:3526–3530.
   PubMed Web of Science ®Google Scholar
• HASEGAWA I, MURAKAWA H, SUZUKI M, YAMAMOTO Y, KURABAYASHI T, TANAKA K: Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fern] Steil] (1999) 71:323–327.
   PubMed Web of Science ®Google Scholar
• MITWALLY MF, KUSCU NK, YALCINKAYA TM: High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum. Reprod. (1999) 14:2700–2703.
   PubMed Web of Science ®Google Scholar
• NESTLER JE, JAKUBOWICZ DJ, REAMER P, GUNN RD, ALLAN G: Ovulatory and metabolic effects of D-chire-inositol in the polycystic ovary syndrome. N. Eng] J. Med. (1999) 340:1314–1320.
   PubMed Web of Science ®Google Scholar
• CRAVE JC, FIMBEL S, LEJEUNE H, CUGNARDEY N, DECHAUD H, PUGEAT M: Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. .j. Clin. Endocrinol Metab (1995) 80:2057–2062.
   PubMed Web of Science ®Google Scholar
• AgBAY 0, GUNDOGDU S: Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertll. Sterll. (1996) 65:946–949.
   PubMed Web of Science ®Google Scholar
• EHRMANN DA, CAVAGHAN MK, IMPERIAL J, STURIS J, ROSENFIELD RL, POLONSKY KS: Effects of metformin on insulin secretion, insulin action and ovarian steroidogenesis in women with polycystic ovary syndrome. I Chi]. Endocrinol. Metab. (1997) 82:524–530.
   PubMed Web of Science ®Google Scholar
• NESTLER JE: Mefformin and the polycystic ovary syndrome. I Chi]. Endocrinol. Metab. (2001) 86:1430.
   PubMed Web of Science ®Google Scholar
• SPRITZER P, BILAUD L, THALABARD JC et al.: Cyproterone acetate versus hydrocortisone treatment in late onset adrenal hyperplasia. j Chi]. Endocrinol. Metab. (1990) 70:642–646.
   PubMed Web of Science ®Google Scholar
• ANTONUCCI T, WHITCOMB R, MCLAIN R, LOCKWOOD D, NORRIS RM: Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care (1997) 20:188–193.
   PubMed Web of Science ®Google Scholar
• LI CL, PAN CY, LU JM etal.: Effect of metformin on impaired glucose tolerance. Diabetes Med. (1999) 16:477–481.
   Google Scholar
• BUCHANAN TA, XIANG AH, PETERS RK etal.: Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for Type 2 diabetes. Diabetes (2000) 49:782–788.
   Google Scholar
• VELAZQUEZ EM, MENDOZA SG, WANG E GLUECK CJ: Mefformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-I, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism (1997) 46:454–457.
   PubMed Web of Science ®Google Scholar
• HENRY RR: Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention. Am. j. Med. (1998) 105(1A):205–265.
   Google Scholar
• INZUCCHI SE, MAGGS DG, SPOLLET GR etal.: Efficacy and metabolic effects of metformin and troglitazone in Type II diabetes mellitus. N Engl. I Med. (1998) 338:867–872.
   Google Scholar
• KORYTKOWSKI MT, MOKAN M, HORWITZ MJ, BERGA SL: Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. j. CM]. Endocrinol. Metab. (1995) 80:3327–3334.
   PubMed Web of Science ®Google Scholar
• ESCOBAR-MORREALE HF, LASUNCION MA, SANCHO J: Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity. Fertil. (2000) 74:816–819.
   PubMed Web of Science ®Google Scholar